Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT00152997
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
- Conditions
- Arthroplasty, Replacement, KneeThromboembolism
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2615
- Registration Number
- NCT00152971
- Locations
- 🇲🇽
1160.24.05009 Traumatologia, Planta Baja, Guadalajara, Jalisco, Mexico
🇺🇸1160.24.01010 MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸1160.24.01033 Bone and Joint Clinic of Houston, Houston, Texas, United States
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy
- Conditions
- Diabetic Nephropathies
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 527
- Registration Number
- NCT00153088
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan
Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 234
- Registration Number
- NCT00157235
- Locations
- 🇮🇹
Fondazione Don Gnocchi, Pozzolatico (FI), Italy
🇮🇹Fondazione "S. Maugeri", Tradate (VA), Italy
🇮🇹Arcispedale S. Anna, Ferrara, Italy
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- AsthmaPulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT00153075
- Locations
- 🇩🇪
Inamed Research GmbH & Co. KG, Gauting, Germany
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
- Conditions
- Cardiovascular Diseases
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31546
- Registration Number
- NCT00153101
- Locations
- 🇺🇸
502.373.0247 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸502.373.0177 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States
🇦🇺502.373.0529 Launceston General Hospital, Launceston, Tasmania, Australia
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
- Conditions
- Pulmonary Disease, Chronic ObstructiveAsthma
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 472
- Registration Number
- NCT00152984
- Locations
- 🇧🇪
Clinique Reine Astrid, Malmedy, Belgium
🇧🇪Sint-Elisabethziekenhuis, Turnhout, Belgium
🇫🇷Hopital Notre Dame de Bon Secours, Metz cedex 1, France
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 254
- Registration Number
- NCT00148512
- Locations
- 🇩🇪
Paracelsus-Elena-Klinik, Kassel, Germany
🇦🇹Univ.-Klinik für Neurologie, Innsbruck, Austria
🇫🇷Hôpital Gabriel Montpied, Clermont Ferrand, France
Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis
- Conditions
- Pharyngitis
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 751
- Registration Number
- NCT00148499
- Locations
- 🇷🇴
Medicover, Bucharest, Romania
🇺🇦City Clinical Otolaryngological Hospital, Kharkov, Ukraine
🇷🇴Victor Babes Clincial Hospital, Bucharest, Romania
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 261
- Registration Number
- NCT00148486
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇨🇦Davidson Memory Clinic, Moncton, New Brunswick, Canada
🇨🇦Centre For Movement Disorders, Markham, Ontario, Canada